Timothy Romberger's most recent trade in Cyteir Therapeutics Inc was a trade of 14,150 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 3, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cyteir Therapeutics Inc | Timothy Romberger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 14,150 | 14,150 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Timothy Romberger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 14,150 | 14,150 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Timothy Romberger | Director | 22 Jun 2021 | 200,000 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Cyteir Therapeutics Inc | Timothy Romberger | Director | 22 Jun 2021 | 79,060 | 369,448 | - | - | Common Stock | ||
| Cyteir Therapeutics Inc | Timothy Romberger | Director | 22 Jun 2021 | 69,503 | 0 | - | - | Series A Convertible Preferred Stock |